Amerikanische Gesellschaft für Hirudotherapie

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for androgenic alopecia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Welche Evidenz existiert?
Tier C (investigational). Two small single-arm case series report modest trichoscopic hair-density increases (about 3 to 7 percent) after 6 monthly sessions; there are no randomized controlled trials. Evidence-based options with FDA approval and decades of data are topical minoxidil 2 percent / 5 percent (men and women), oral finasteride 1 mg (men), oral dutasteride (off-label, robust evidence), low-level laser therapy devices, and platelet-rich plasma injections. Hair transplantation is the definitive option for advanced loss.
Hauptrisiken
  • Bleeding from bite sites on the scalp for 6 to 24 hours after detachment
  • Bruising and tenderness over the scalp for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary telogen effluvium (stress-related shedding) at the application sites
  • Cosmetic visible small scars at bite sites
  • Wasted time and money if used INSTEAD OF proven minoxidil, finasteride, or transplantation
Wer dies nicht in Betracht ziehen sollte
  • Patients with active scalp infection, seborrheic dermatitis, or psoriasis at proposed sites
  • Patients within 3 months of a hair transplant procedure
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with undiagnosed hair loss (need to rule out telogen effluvium, alopecia areata, scarring alopecia)
  • Patients who have not tried evidence-based first-line therapy (minoxidil for both sexes; finasteride for men)
  • Patients with active scalp malignancy or atypical nevi at proposed sites
Was Sie Ihren Kliniker fragen sollten
  • Has my hair loss been confirmed as androgenic alopecia (Norwood scale for men, Ludwig for women)?
  • Have I tried topical minoxidil (5 percent) consistently for at least 6 months?
  • Am I a candidate for oral finasteride (men) or dutasteride / spironolactone (women off-label)?
  • Have I considered low-level laser therapy, PRP, or hair transplantation?
  • What is the realistic effect size with leech therapy versus proven options?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost compared to evidence-based therapy?
Wann dringende medizinische Versorgung suchen
  • Spreading redness, warmth, pus, or red streaks on the scalp (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Sudden patchy hair loss with smooth bald patches (alopecia areata — needs dermatology evaluation)
  • Scalp scarring, redness, or pain with hair loss (scarring alopecia — needs urgent dermatology evaluation)
  • Hives, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is not FDA-cleared for androgenic alopecia.
  • Small uncontrolled series with modest density changes do NOT establish efficacy versus minoxidil or finasteride.
  • Mechanism rationale (microcirculatory improvement, growth-factor stimulation) does NOT establish clinical efficacy.
  • Leech therapy is not a substitute for proven topical minoxidil, oral finasteride / dutasteride, PRP, or hair transplantation.
  • Hair loss progression cannot be halted by leech therapy in the way that 5-alpha-reductase inhibitors have been shown to do.

Clinical Profile

Category
dermatological
ICD-10
L64.0, L64.8, L64.9
Safety tier
low

Evidence Summary

No controlled trial or quantified case series of leech therapy for androgenic alopecia has been published; use is investigational and mechanistic only. The speculative rationale is local microcirculatory improvement plus growth-factor stimulation of the scalp, but no clinical evidence supports an increase in hair density or terminal hair count. It is too preliminary to recommend over established treatments (minoxidil, finasteride, low-level laser therapy, PRP). Although it is sometimes combined with PRP in integrative protocols, no controlled comparison exists. ASH position: investigational only, with no demonstrated benefit.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Khan MA et al. (2020), n=24

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active scalp infection or seborrheic dermatitis
  • Recent (<3 months) hair transplant

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Androgenic Alopecia — Hirudotherapy Evidence | ASH